Clinical significance of sCD105 in angiogenesis and disease activity in multiple myeloma

European Journal of Internal Medicine

Volumn 23, Issue 4, 2012, Pages 368-373

  Tsirakis, G ^a   Pappa, C A ^b   Spanoudakis, M ^a   Chochlakis, D ^c   Alegakis, A ^c   Psarakis, F E ^b   Stratinaki, M ^b   Stathopoulos, E N ^a   Alexandrakis, M G ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b Venizelion General Hospital   (Greece)

^c UNIVERSITY OF CRETE   (Greece)

Author keywords

Angiogenesis; Cytokines; Myeloma; Proliferation; sCD105

Indexed keywords

ENDOGLIN; INTERLEUKIN 6; KI 67 ANTIGEN; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BLOOD LEVEL; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, CD38; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-6; KI-67 ANTIGEN; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOVASCULARIZATION, PHYSIOLOGIC; RECEPTORS, CELL SURFACE; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84860526101     PISSN: 09536205     EISSN: 18790828     Source Type: Journal    
DOI: 10.1016/j.ejim.2012.01.012     Document Type: Article

References (39)

1. J. Folkman Seminars in medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis N Engl J Med 333 1995 1757 1763
2. A. Vacca, D. Ribatti, L. Roncali, G. Ranieri, G. Serio, and F. Silvestris Bone marrow angiogenesis and progression in multiple myeloma Br J Haematol 87 1994 503 508
3. S. Kumar, T.E. Witzig, M. Timm, J. Haug, L. Wellik, and T.K. Kimlinger Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression Blood 104 2004 1159 1165
4. F. Di Raimondo, M.P. Azzaro, G. Palumbo, S. Bagnato, G. Giustolisi, and P. Floridia Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheralblood Haematologica 85 2000 800 805
5. M.G. Alexandrakis, F.J. Passam, E. Ganotakis, E. Dafnis, C. Dambaki, and J. Konsolas Bone marrow microvascular density and angiogenic growth factors in multiple myeloma Clin Chem Lab Med 42 2004 1122 1126
6. S.V. Rajkumar, R.A. Mesa, R. Fonseca, G. Schroeder, M.F. Plevak, and A. Dispenzieri Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis Clin Cancer Res 8 2002 2210 2216
7. N. Takahashi, R. Kawanishi-Tabata, A. Haba, M. Tabata, Y. Haruta, and H. Tsai Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin Clin Cancer Res 7 2001 524 532
8. T. Sánchez-Elsner, L.M. Botella, B. Velasco, C. Langa, and C. Bernabéu Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-beta pathways J Biol Chem 277 2002 43799 43808
9. S.E. Duff, C. Li, J.M. Garland, and S. Kumar CD105 is important for angiogenesis: evidence and potential applications FASEB J 17 2003 984 992
10. S. Cheifetz, T. Bellón, C. Calés, S. Vera, C. Bernabeu, and J. Massagué Endoglin is a component of the transforming growth factor-beta receptor system in human endothelialcells J Biol Chem 267 1992 19027 19030
11. M. Urashima, A. Ogata, D. Chauhan, M. Hatziyanni, M.B. Vidriales, and D.A. Dedera Transforming growth factor-beta1: differential effects on multiple myeloma versusnormal B cells Blood 87 1996 1928 1938
12. A.B. Roberts Molecular and cell biology of TGF-beta Miner Electrolyte Metab 24 1998 111 119
13. M.S. Pepper Transforming growth factor-beta: vasculogenesis, angiogenesis, and vessel wall integrity Cytokine Growth Factor Rev 8 1997 21 43
14. C. Li, B. Guo, P.B. Wilson, A. Stewart, G. Byrne, and N. Bundred Plasma levels of soluble CD105 correlate with metastasis in patients with breast cancer Int J Cancer 89 2000 122 126
15. L. Calabrò, E. Fonsatti, G. Bellomo, A. Alonci, F. Colizzi, and L. Sigalotti Differential levels of soluble endoglin (CD105) in myeloid malignancies J Cell Physiol 194 2003 171 175
16. E. Fonsatti, L. Del Vecchio, M. Altomonte, L. Sigalotti, M.R. Nicotra, and S. Coral Endoglin: An accessory component of the TGF-beta-binding receptor-complex with diagnostic,prognostic, and bioimmunotherapeutic potential in human malignancies J Cell Physiol 188 2001 1 7
17. B.G. Durie, and S.E. Salmon A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival Cancer 36 1975 842 854
18. J.M. Wang, P.B. Wilson, S. Kumar, D. Pye, and R.D. Hunter Quantitation of endothelial cell specific protein E-9 employing a single monoclonal antibody in an indirect sandwich ELISA J Immunol Methods 171 1994 55 64
19. F.J. Burrows, E.J. Derbyshire, P.L. Tazzari, P. Amlot, A.F. Gazdar, and S.W. King Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy Clin Cancer Res 1 1995 1623 1634
20. B. Bodey, B. Bodey Jr., S.E. Siegel, and H.E. Kaiser Over-expression of endoglin (CD105): a marker of breast carcinoma-induced neo-vascularization Anticancer Res 18 1998 3621 3628
21. J.M. Wang, S. Kumar, D. Pye, N. Haboubi, and L. al-Nakib Breast carcinoma: comparative study of tumor vasculature using two endothelial cell markers J Natl Cancer Inst 86 1994 386 388
22. N. Weidner Tumoural vascularity as a prognostic factor in cancer patients: the evidencecontinues to grow J Pathol 184 1998 119 122
23. A. Aguayo, H. Kantarjian, T. Manshouri, C. Gidel, E. Estey, and D. Thomas Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes Blood 96 2000 2240 2245
24. L.G. Lundberg, R. Lerner, P. Sundelin, R. Rogers, J. Folkman, and J. Palmblad Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity Am J Pathol 157 2000 15 19
25. M.G. Alexandrakis, F.H. Passam, D.S. Kyriakou, C. Dambaki, G. Katrinakis, and G. Tsirakis Expression of the proliferation-associated nuclear protein MIB-1 and its relationshipwith microvascular density in bone marrow biopsies of patients with myelodysplastic syndromes J Mol Histol 35 2004 857 863
26. A. Vacca, and D. Ribatti Angiogenesis and vasculogenesis in multiple myeloma: role of inflammatory cells Recent Results Cancer Res 183 2011 87 95
27. K.C. Anderson Moving disease biology from the lab to the clinic Cancer 97 2003 796 801
28. G. Pruneri, M. Ponzoni, A.J. Ferreri, N. Decarli, M. Tresoldi, and F. Raggi Microvessel density, a surrogate marker of angiogenesis, is significantly related to survival in multiple myeloma patients Br J Haematol 118 2002 817 820
29. C. Li, I.N. Hampson, L. Hampson, P. Kumar, C. Bernabeu, and S. Kumar CD105 antagonizes the inhibitory signaling of transforming growth factor beta1 on human vascular endothelial cells FASEB J 14 2000 55 64
30. H. Zhang, V. Vakil, M. Braunstein, E.L. Smith, J. Maroney, and L. Chen Circulating endothelialprogenitor cells in multiple myeloma: implications and significance Blood 105 2005 3286 3294
31. Y.M. El-Gohary, J.F. Silverman, P.R. Olson, Y.L. Liu, J.K. Cohen, and R. Miller Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in prostatic adenocarcinoma Am J Clin Pathol 127 2007 572 579
32. Y. Takase, K. Kai, M. Masuda, M. Akashi, and O. Tokunaga Endoglin (CD105) expression and angiogenesis status in small cell lung cancer Pathol Res Pract 206 2010 725 730
33. C. Li, R. Gardy, B.K. Seon, S.E. Duff, S. Abdalla, and A. Renehan Both high intratumoral microvessel density determined using CD105 antibody and elevated plasma levels of CD105 in colorectal cancer patients correlate with poor prognosis Br J Cancer 88 2003 1424 1431
34. V.M. Lauta A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications Cancer 97 2003 2440 2452
35. B. Dankbar, T. Padró, R. Leo, B. Feldmann, M. Kropff, and R.M. Mesters Vascular endothelialgrowth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma Blood 95 2000 2630 2636
36. K.C. Anderson Moving disease biology from the laboratory to the clinic Semin Oncol 29 2002 17 20
37. J. Thaler, F. Fechner, M. Herold, and H. Huber Interleukin-6 in multiple myeloma: correlation with disease activity and Ki-67 proliferation index Leuk Lymphoma 12 1994 265 271
38. H.S. Oh, J.H. Choi, C.K. Park, C.W. Jung, S.I. Lee, and Q. Park Comparison of microvessel density before and after peripheral blood stem cell transplantation in multiple myeloma patients and its clinical implications: multicenter trial Int J Hematol 76 2002 465 470
39. S. Kumar, R. Fonseca, A. Dispenzieri, M.Q. Lacy, J.A. Lust, and T.E. Witzig Bone marrow angiogenesis in multiple myeloma: effect of therapy Br J Haematol 119 2002 665 671